Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma

Table 3 Anti-tumour effects: clinical efficacy

Antitumor response	Level 1	Level 2	Level 3
	n, (Case number)
CR	0	0	0
PR	0	0	1, (Case 9)
SD	1, (Case 1)	2, (Case 4, 6)	1, (Case 8)
PD	1, (Case 2)	1 (Case 5)	1, (Case 7)
Not evaluable	1, (Case 3)	0	0
DCR (%)	50	66.7	66.7
Period of follow up (day)
Median	120	87	83
Range	50-213	24-140	54-84

Modified Response Evaluation Criteria In Solid Tumors guidelines were followed to evaluate anti-tumour effects. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate.

ISSN: 1471-230X